2 of 4
M. Schmutz, A. Arthur, H. Faleck, G. Karlsson, A. Kotake, L. Landwicki, L. LaRue, S. Markabi, D. Murphy, M. Powell, and D. Sauer, Selfotel.P. Herrling et al., D-CPPene (SDZ EAA-494) A Competitive NMDA Antagonist: Pharmacology and Results in Humans.J.D. Kristensen, Intrathecal Administration of a Competitive NMDA Receptor Antagonist for Pain Treatment.A.G. Knapp, L.I. Matthews, and E.R. Gamzu, Clinical Experience with the NMDA Ion-Channel Blocker, Aptiganel Hydrochloride (CEROSTAT).M.-L. Maccecchini, Development of ACPC: A Partial Agonist of the Glycine Site on the NMDA Receptor.Carter et al., Ifenprodil and Eliprodil: Neuroprotective NMDA Receptor Antagonists and Calcium Channel Blockers.D. Lodge and D.D. Schoepp, 3S, 8aR-6-[2-(1(2)H-tetrazole-5-y)ethyl] Decahydroisoquinoline-3-carboxylic Acid (LY293558) and Its Racemate (LY215490): A Selective and Competitive AMPA/Kainate Receptor Agonist.L. Nordholm, M. Sheardown, and T. Honore, The NBQX Story.E. Louvel, Riluzole in Amytrophic Lateral Sclerosis.G.C. Plamer and J.B. Hutchinson, Preclinical and Clinical Aspects of Remacemide Hydrochloride.
Note: Product cover images may vary from those shown